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During the post-prandial phase, intestinal triglyceride-rich lipoproteins (TRL) i.e. chylomicrons are the
main contributors to the serum lipid level, which is linked to coronary artery diseases. Hyper-
triglyceridemia can originate from decreased clearance or increased production of TRL. During lipid
absorption, enterocytes produce and secrete chylomicrons and transiently store lipid droplets (LDs) in
the cytosol. The dynamic ﬂuctuation of triglycerides in cytosolic LDs suggests that they contribute to TRL
production and may thus control the length and amplitude of the post-prandial hypertriglyceridemia. In
this review, we will describe the recent advances in the characterization of enterocytic LDs. The role of
LDs in chylomicron production and secretion as well as potential previously unsuspected functions in the
metabolism of vitamins, steroids and prostaglandins and in viral infection will also be discussed.
 2013 The Authors. Published by Elsevier Masson SAS. Open access under CC BY-NC-SA license.Fat absorption by the small intestine is a very efﬁcient process.
Triglycerides (TG) are exported from enterocytes as chylomicrons
that are triglyceride-rich lipoproteins (TRL). They are subsequently
hydrolyzed in the circulation to provide the body with fatty acids.
Thus, serum lipid levels result from the production of lipoproteins
by liver and intestine and from their clearance. Chylomicrons
are important contributors to the circulating lipids during theomain 5/comparative gene
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r Masson SAS. Open access under CC BYpost-prandial state and it is well established that post-prandial
serum lipid levels have a positive correlation with coronary artery
diseases [1,2]. Recent studies have shown that a transient formation
of lipid droplets (LDs) in the cytosol of enterocytes may be a part of
the physiological process contributing to chylomicron assembly and
secretion after a meal, and thus to the control of the amplitude and
duration of postprandial hypertriglyceridemia [3,4]. Despite their
promising impact in the understanding of metabolic disorders, the
molecular mechanisms governing intestinal cytosolic LD formation
and mobilization and triglyceride distribution between the cytosol
for transient storage and the endoplasmic reticulum (ER) lumen for
chylomicron assembly, are only beginning to be explored. Although
chylomicrons and cytosolic LDs are both composed of a core of
neutral lipids (TG and cholesterol esters) surrounded by a mono-
layer of amphipathic lipids (phospholipids and cholesterol), they
differ in many aspects as summarized in Table 1.
In this review, wewill present the links between the production
and metabolism of chylomicrons and the risk factors of cardiovas-
cular diseases. We will review the present knowledge on enter-
ocyte cytosolic LDs including their dynamics and composition, and
we will discuss their potential roles in the control of chylomicron
assembly and production, as well as their potential functions in the
metabolism of hydrophobic molecules (summarized in Fig. 1).-NC-SA license.
Table 1
Differences between cytosolic lipid droplets and chylomicrons.
Cytosolic lipid droplet Chylomicron
Size Up to 6 mm
(non adipocyte LDs)
75e1200 nm
Localization Cytosol Lumen of the secretory
pathway (endoplasmic
reticulum, Golgi apparatus)
and extracellular
Speciﬁc protein coat
Apolipoprotein B No Yes
Perilipin family Yes No
Function Intracellular
lipid storage
Lipid distribution to the body
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Chylomicrons are mainly produced by the jejunum after a meal,
during the post-prandial phase. They are low density particles
(d < 1.006 g/mL) and are very heterogeneous in size (diameters
75e1200 nm) [5,6]. A chylomicron is composed of a core of neutral
lipids (more than 90%), predominantly TG, with traces of choles-
teryl ester, stabilized by a shell of amphipathic lipids (phospho-
lipids, cholesterol) and one structural protein, the apolipoprotein
(apo) B48, as well as other exchangeable apolipoproteins [7]. In the
blood circulation, TG derived from the chylomicrons are hydrolyzed
by lipoprotein lipase into fatty acids that are taken up by organs
such as the skeletal muscles and the heart for energy supply, or the
adipose tissue for storage. The chylomicron remnants are taken up
primarily by the liver, especially by the low density lipoprotein
(LDL) receptor that has a high afﬁnity for apoE, but other routes are
involved including the LDL receptor-related protein 1 (LRP1) and
the heparin sulfate proteoglycan (HSPG) pathway (for review, see
Refs. [8e10]).Fig. 1. Schematic model of neutral lipid distribution and trafﬁcking in enterocytes, with
functions. Triglycerides (TG), the main dietary lipid, are hydrolyzed in the lumen of the je
enterocytes and metabolized into TG at the endoplasmic reticulum (ER) membrane. The ne
membrane. A nascent LD buds off the ER in the ER lumen and fuses with an apoB48/PL-rich
the basal pole of enterocytes to provide lipids to the body. Microsomal triglyceride transfer p
LDs also bud off the ER in the cytosol for transient lipid storage. They will be mobilized be
Additional potential functions of cytosolic LDs in enterocytes are indicated.Cardiovascular diseases, type 2 diabetes and dyslipidemia are
comorbidities of obesity [11]. Chylomicron metabolism can
contribute to the development of these diseases. First, being
directly exposed to dietary fat, the small intestine is instrumental in
the control of the amount of lipids that enter the body and might
contribute to the development of obesity. Second, liver and intes-
tine produce TRL, called very low density lipoproteins (VLDL) and
chylomicron respectively, and, under post-prandial conditions, the
chylomicrons are important contributors to the circulating lipids.
Furthermore, post-prandial serum lipid levels have a stronger
positive correlation with coronary artery diseases than the fasting
serum lipid levels [1,2]. Third, chylomicron remnants can rapidly
penetrate the arterial wall suggesting a contribution in athero-
sclerosis development [12,13]. Fourth, an accumulation of lipo-
proteins in the plasma can result from decreased catabolism but
also from increased production rates. Intestinal apoB48 lipoprotein
overproduction was demonstrated for the ﬁrst time in an insulin-
resistant animal model, the fructose fed hamster [14]. This dem-
onstrates that the intestine is not just an absorptive organ: it is also
able to modulate lipoprotein production, a capacity previously
strictly devoted to the liver.
Overall, establishing strategies to optimize chylomicron meta-
bolism in order to reduce postprandial lipemia and chylomicron
remnant accumulation would be a promising avenue for the pre-
vention of cardiovascular diseases.
2. Chylomicron assembly and secretion
2.1. Chylomicron assembly: a two-step process
Absorption of dietary lipids by the enterocytes of the jejunum is
a highly specialized and complex process (Fig. 1) (for reviews, see
Refs. [15e17]). The hydrolysis of TG, which is the main dietary lipid,
initiates in the stomach by the gastric lipase then in the lumen of
the upper part of the small intestine by pancreatic lipase and leadsa focus on chylomicron (CM) and cytosolic lipid droplets (LDs) biogenesis, fate, and
junum into fatty acids (FA) and 2-monoacylglycerols (2-MG), which are taken up by
wly synthesized TGs accumulate between the two leaﬂets of the ER phospholipid (PL)
particle to form a CM that will trafﬁc along the Golgi apparatus and will be secreted at
rotein (MTP) is required for CM assembly. After an acute dietary lipid load, the nascent
tween meals for CM formation through hydrolysis/re-esteriﬁcation and/or autophagy.
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originating from both the bile and the diet are hydrolyzed by the
pancreatic phospholipase A2 into lysophosphatidylcholine (lysoPC)
and fatty acids. These lipids are taken up by the enterocytes by
passive diffusion and/or transporters. TG and phospholipids are
subsequently synthesized at the ER membrane. TG are mainly
synthesized by the monoacylglycerol pathway. Monoacylglycerol:
acylCoA transferase (MGAT) converts monoacylglycerol and fatty
acids into diacylglycerol, which is in turn converted to TG by
diacylglycerol: acylCoA transferase (DGAT). As documented for
VLDL assembly in hepatocytes, chylomicron assembly occurs via a
two-step process in the secretory pathway [18,19]. Dense apoB48
phospholipid-rich particles are ﬁrst produced, and they subse-
quently fuse with a LD formed independently in the ER lumen,
giving rise to large-sized chylomicron particles (Fig. 1). The
microsomal triglyceride transfer protein (MTP) is necessary for
both steps. Once matured and trafﬁcked through the Golgi appa-
ratus, the chylomicrons are secreted at the basal pole of the
enterocytes. Exchangeable apos, including apoA-IV and apoC-III,
are suggested to facilitate different stages of chylomicron assem-
bly and trafﬁcking through the EReGolgi secretory compartments
[20]. The maturation and the subsequent secretion of chylomicrons
are also dependent on proper ER-to-Golgi and intra/post-Golgi
trafﬁcking steps. In this context, several membrane trafﬁcking
regulators of the biosynthetic pathway have been directly involved
in lipoprotein lipidation and/or maturation, such as COPII complex
[21,22] or ADP-ribosylation factor related protein 1 (ARFRP1) [23], a
small GTPase. ARFRP1 has been also proposed to act in lipid droplet
growth in adipocytes [24].
2.2. The chylomicron: a versatile lipoprotein particle
Lipid availability in the ER lumen plays a pivotal role in the
regulation of chylomicron production. An increase of the TG load
transported by the chylomicrons can result from the production of
an increased number of chylomicrons of similar sizes, or from the
production of a similar number of chylomicrons with an increased
particle size, or from the increase of both size and number of chy-
lomicrons. It is important to make the distinction between particle
number and particle size, because the production of an increased
number of particles will lead to an increased number of chylomi-
cron remnants, hence potentially to an increased risk of athero-
sclerosis [12,25].
The impact of insulin and of insulin resistance on lipoprotein
production has been studied (for reviews, see Refs. [12,17,25e27]).
Insulin inhibits TRL production in the liver and in the intestine.
Under conditions of insulin resistance, intestinal TRL production is
stimulated because of an elevated ﬂux of free fatty acids into the
intestine, accompanied by the down-regulation of intestinal insulin
signaling and the upregulation of MTP levels. In diabetic animal
models, alteration of the number and/or of the size of chylomicrons
has been reported. However, except for the role of MTP, the mo-
lecular mechanisms governing the formation of the LDs in the ER
lumen and the control of the TG core size of chylomicrons are still
unclear.
Small dense apoB-48 phospholipid-rich particles (i.e. TG poor)
are secreted by enterocytes from hamsters or rabbits fed a low fat-
diet [25]. Similarly, Caco-2 cells, an in vitro model for human
enterocytes, secrete a substantial amount of small dense apoB48
phospholipid-rich particles [28e30].
3. Cytosolic lipids droplets in enterocytes
As underlined by recent reviews [31e33], cytosolic LDs are
composed of a core of TG and cholesterol esters surrounded by amonolayer of phospholipids, cholesterol and of a variety of proteins
(Fig. 1). Recent advances have revealed LDs to be dynamic struc-
tures that are able to communicate and interact with other intra-
cellular compartments [32,34]. The onset of LD biogenesis is widely
accepted as being the accumulation of newly synthesized TG be-
tween the two leaﬂets of the ER phospholipid bilayer [35e37].
Several models have been proposed for the later stages of biogen-
esis [38,39]. In all cell types, the nascent LD buds off the ER into the
cytosol, while in hepatocytes and enterocytes it can bud also to-
wards the ER lumen where TRL assembly takes place leading to
lipid secretion. The mechanisms that control the lipid distribution
between the cytosol and the ER lumen are still unclear.
LDs are coated by a variety of proteins, as demonstrated by
several proteomics studies that have been undertaken on LDs iso-
lated from various sources [40,41]. The proteome of the LD includes
structural proteins of the perilipin family (perilipins 1e5, previ-
ously known as PAT family proteins), proteins involved in lipid
metabolism, membrane trafﬁcking, signaling, cytoskeleton and
chaperones. These studies have revealed the complexity of the LD
coat. It can differ from one cell type to another as well as within a
single cell where different populations of LDs can co-exist, and can
vary depending on the physiopathology of the cell.
3.1. Dynamics of cytosolic lipid droplets in enterocytes
Cytosolic LDs have been observed in jejunal enterocytes during
lipid absorption in rats [42], mice [43], golden hamsters [44], rab-
bits [45], pigs [46] and humans [47]. Moreover, they have recently
been shown to be very dynamic organelles. By CARS (coherent anti-
stokes Raman scattering) imaging [3,48] and electron microscopy
[4], mouse jejunal enterocytes were shown to exhibit many cyto-
solic LDs at their apical pole after oil gavage. Remarkably, the LDs
are absent 12 h later. Since their lipid content is exported later as
chylomicrons, cytosolic LDs can thus be considered as important
contributors to the control of postprandial triglyceridemia.
In the human jejunum, LDs of up to 6 mmdiameter are present in
enterocytes 6 h after a fat load. As compared to water, ingestion of
glucose leads to a lower intracellular TG content and increased
chylomicron secretion, suggesting that carbohydrate and fat inﬂu-
ence each other’s metabolism [47]. Recent studies conducted in ob/
ob mice and high-fat diet-fed mice showed an altered TG handling
by the small intestine compared to lean mice i.e. the accumulation
of mucosal TG possibly secondary to a decreased lipid secretion
[49,50].
3.2. Proteome of lipid droplets isolated from enterocytes
Several studies have highlighted recently the proteins associ-
ated with cytosolic LDs in enterocytes. Perilipin 2 (ADRP) and
perilipin 3 (TIP47) are the only members of the perilipin family
expressed in mouse enterocytes in vivo [48]. Unfortunately, the
proteome of LDs isolated from the jejunal enterocytes has not yet
been investigated. However, the LD proteome of Caco-2 cells, a cell
culturemodel of human enterocytes that is able to secrete TRL upon
lipid supply [29,30,51], has been described. Of the proteins iden-
tiﬁed in LD fractions isolated from Caco-2 cells, one-quarter were
directly involved in lipid metabolism pathways potentially relevant
to enterocyte-speciﬁc functions including fatty acid activation, tri-
glyceride hydrolysis, phospholipid metabolism, lipoprotein meta-
bolism, steroid metabolism, etc [4]. More recently, by a differential
proteomic approach, the proteins associated with LDs that were
altered by hepatitis C virus (HCV) core protein expression were
identiﬁed [52]. HCV core protein is known to localize onto LDs and
to impair TG secretion in hepatocytes [53]. A set of 16 proteins
was characterized and most of these hits were involved in lipid
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secretion, the array of proteins identiﬁed might be involved in the
balance between lipid storage as LDs and lipid secretion as TRL.
A diversity of proteins known to be associated with organelles
such as the ER, mitochondria or peroxisomes were identiﬁed in the
LD fractions isolated from the Caco-2 enterocytes [4,52]. This
feature has been previously reported in LD fractions isolated from
other cell types [41] and these organelles are particularly abundant
in the cytoplasm of Caco-2 cells. Caution should be used in classi-
fying these proteins as contaminants because it has been demon-
strated recently that proteins with a hairpin-like monotopic
topology are targeted to both the ER membrane and the LD hemi-
membrane [54,55], and because the previous localization studies
were generally undertaken in the absence of added fatty acids,
which are required to induce clearly visible LD formation.
4. Functions of the cytosolic lipid droplets in enterocytes
4.1. Role in transient lipid storage and lipoprotein production
between meals
Observations made in enterocytes in vivo during lipid absorp-
tion have clearly shown dynamic accumulation and depletion of TG
in cytosolic LDs during the process of fat absorption [3,4,47]. To
what extent these processes are controlled and may contribute to
intestinal adaptation/modulation of lipoprotein production is
unclear.
In Caco-2 cells, TG stored as cytosolic LDs can be mobilized to
contribute to TRL production [29] and TG distribution between
cytosol and ER can be modulated by nutrients [30]. By differential
proteomics, Beilstein et al. [52] identiﬁed proteins potentially
involved in the control of the balance between lipid storage and
secretion among which the two proteins of the perilipin family that
are expressed by enterocytes, perilipin 2 and perilipin 3. Perilipin 2
is unstable when not bound to LDs while perilipin 3 is present in
the cytosol when LDs are absent. Studies to elucidate the functions
of perilipins include gain- and loss-of-function experiments in cells
and gene targeting and silencing in mice (for reviews, see Refs.
[56,57]). The effects of gain- and loss-of-function differ from cell
type to cell type and from tissue to tissue. The function(s) of per-
ilipin 2 and 3 in jejunum has not yet been investigated. Overall,
perilipin 2 is suggested to stabilize long term-stored TG by limiting
the interactions of lipases with the LDs. Although less effective,
perilipin 3 is suggested to have a similar function. Moreover,
perilipin 3 is predominantly localized on nascent LDs and has been
suggested to be involved in LD synthesis from newly synthesized
TG. In mice, perilipin 2 and 3 are expressed differently inTable 2
Proteins associated with LDs from enterocytic cells that may be involved in lipid mobiliz
Name Protein name
ACSL 3 Long chain acyl-CoA synthetase 3
ACSL 4 Long chain acyl-CoA synthetase 4
ACSL 5 Long chain acyl-CoA synthetase 5
ABHD5/CGI-58 a/b Hydrolase domain 5/comparative gene identiﬁcation-58
ATGL Adipose triglyceride lipase
CCT-a Choline-phosphate cytidylyltransferase A
HSL Hormone sensitive lipase
LPCAT2 Lysophosphatidylcholine acyltransferase 2
MGAT2 Monoacylglycerol: acylCoA transferase 2
MGL Monoglyceride lipase
MTP Microsomal triglyceride transfer protein
PLIN2 Perilipin 2/ADRP
PLIN3 Perilipin 3/TIP47
UBXD8/FAF2 UBX domain-containing protein 8/FAS-associated factor 2enterocytes depending upon the diet and whether an acute or
chronic high fat diet is ingested [48]. In hepatic cells, perilipin 2
overexpression results in increased accumulation of cytosolic LDs
and a corresponding decrease of VLDL secretion [58]. Overall, in
enterocytes, one can hypothesized that, by controlling lipolysis at
the LD surface, perilipins control lipid availability for TG synthesis
at the ER membrane. Furthermore, Beilstein et al. [52] showed an
alteration of the amount of ER-associated proteins, suggesting that
the interactions that occur between LD and the ER, where TRL as-
sembly occurs, are important. Unfortunately, the potential in-
teractions between LDs and various organelles, and their functional
consequences, are still difﬁcult to observe and to interpret [59] but
they may be crucial for chylomicron assembly.
The mobilization of cytosolic triglycerides for the production of
lipoproteins may occur through two processes: hydrolysis/re-
esteriﬁcation and/or autophagy (Fig. 1).
4.1.1. Lipid mobilization for lipoprotein assembly by a mechanism of
hydrolysis/re-esteriﬁcation
In enterocytes, the TGs present in cytosolic LDs are thought to
contribute to chylomicron assembly through a mechanism of
hydrolysis/re-esteriﬁcation as it occurs in hepatocytes (for review,
see Ref. [60] and references therein). We will focus here on the
proteins identiﬁed in cytosolic LD fractions that may be involved in
this process (Table 2). For the factors localized in the ER lumen
including MTP and apos, readers are referred to recent reviews
([15] for enterocytes; [20,61] for hepatocytes).
TG hydrolysis involves several enzymes: adipose triglyceride
lipase (ATGL) that hydrolyzes TG into diacylglycerols and fatty
acids, hormone-sensitive lipase (HSL) that hydrolyzes diac-
ylglycerol into monoacylglycerol and fatty acids, and mono-
acylglycerol lipase (MGL) that hydrolyzes monoacylglycerol into
glycerol and fatty acids (for review, see Ref. [62]). These lipids can
be substrates of MGATs and DGATs for re-synthesis of TG at the ER
membrane for chylomicron assembly.
ATGL and ABHD5/CGI-58, a coactivator of ATGL, were identiﬁed
on the LDs of Caco-2 enterocytes [4] and mouse intestinal mucosa
[63]. In addition to being an activator of ATGL, ABHD5/CGI-58 has
been suggested to play a role in TRL production in hepatocytes and
this should now be examined in enterocytes [64e66]. Further-
more, it has been shown recently in the liver that knockdown of
ABHD5/CGI-58 leads to the sequestration of diacylglycerol in LDs/
ER, preventing diacylglycerol association with the plasma mem-
brane, activation of PKCε, and induction of hepatic insulin resis-
tance [67]. Thus, it should be determined whether a similar
mechanism occurs in the intestine, which is also an insulin sen-
sitive organ [68].ation for lipoprotein assembly by a mechanism of hydrolysis/re-esteriﬁcation.
Function in hydrolysis/re-esteriﬁcation References
Fatty acid activation [4,52]
Fatty acid activation [4]
Fatty acid activation [52]
ATGL activation [4,52]
Triglyceride hydrolysis [4,52,63]
Phosphatidylcholine synthesis [4]
Diglyceride hydrolysis [63]
Phosphatidylcholine synthesis, phospholipid remodeling [4,52]
Diglyceride synthesis [63]
Monoglyceride hydrolysis [4,52]
Lipoprotein assembly (luminal lipid droplet formation,
apolipoprotein B stabilization)
[4,52,63]
Interactions of lipases with LD restricted [4,48,52,63]
Interactions of lipases with LD restricted [4,48,52]
ATGL inhibition [4,52]
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LDs isolated from Caco-2 enterocytes [4,52], localizes to both the ER
and to LDs and it appears to be involved in multiple functions
related to lipid and lipoprotein metabolism. It is a sensor for un-
saturated fatty acids and a regulator of TG synthesis [69]. It also
plays a role in the dislocation and degradation of lipidated apoB100
in Huh-7 hepatic cells [70]. Furthermore, it was recently shown that
UBXD8/FAF2 binds directly to ATGL and promotes its dissociation
from ABHD5/CGI-58 resulting in inhibition of lipase activity [71].
The speciﬁc role of UBXD8/FAF2 in the control of lipid and lipo-
protein metabolism would be very interesting to investigate in the
intestine.
DGAT2 has been found previously to associate with LDs during
TG synthesis in ﬁbroblasts and adipocytes [72] whereas it was not
found in LD fractions isolated from Caco-2 enterocytes [4]. Inter-
estingly, whereas the mouse intestine expresses both DGAT1 and
DGAT2, the human intestine only expresses DGAT1 [73] suggesting
that TG synthesis and hydrolysis are more strictly compartmen-
talized in humans than in mice. Also, the human liver expresses
both DGATs, suggesting that the control of hydrolysis/re-
esteriﬁcation might be different in the intestine and the liver.
Because several proteins/enzymes that are involved in TG
metabolism are localized at the surface of LDs and because the TG
core volume of LDs can vary signiﬁcantly, all proteins/enzymes that
impact the size of LDs can in turn control TG metabolism including
TRL production. Proteins of the cell death-inducing DNA fragmen-
tation factor 45-like effector (CIDE) family, localized on LDs and ER,
appear to play a unique role in controlling the size of cytosolic LDs
in various cell types (see for review [74]). In the liver, VLDLs
secreted from Cideb deﬁcient hepatocytes contain signiﬁcantly less
TG, indicating an impairment in VLDL lipidation [74], and Cideb and
perilipin 2 were shown to play opposing roles in controlling VLDL
lipidation and hepatic lipid homeostasis [75]. However, although
Cideb is expressed markedly in the liver it is expressed much less in
the small intestine [74] and may not be as important in the control
of chylomicron lipidation in the enterocytes. Other candidates able
to impact the size of LDs are the enzymes controlling the phos-
pholipid monolayer of LDs, mainly composed of phosphatidylcho-
line (PC) [76]. Choline-phosphate cytidylyltransferase A (CCT-a),
which catalyzes the rate-limiting step for the synthesis of PC in the
choline pathway, translocates to the LD surface upon oleate addi-
tion and its knockdown leads to fewer LDs of larger size [77]. Liver-
speciﬁc CCT-a KO mice display impaired VLDL secretion in the
plasma [78]. Lysophosphatidylcholine acyltransferases (LPCAT) 1
and 2 have been shown to localize both to the ER and the LDs in
different cell lines including Caco-2 enterocytes [4,79]. In Huh-7
cells, LPCAT1 and 2 knockdowns resulted in an increase of LD size
[79] and, in Caco-2 enterocytes, the amount of LPCAT2 on LDs was
found to be altered by HCV core protein expression [52]. Recently,
knockdown of LPCAT3 in the liver was shown to promote VLDL
production by inducing MTP expression through the accumulation
of lysoPC [80]. In the intestine, a large source of lysoPC comes from
the lumenal hydrolysis of dietary and biliary PC. By controlling the
amount of lysoPC, LPCATs may contribute to intestinal TG homeo-
stasis and the regulation of chylomicron production. The role of
these proteins in the hydrolysis/re-esteriﬁcation process and
chylomicron production remains to be explored.
4.1.2. Lipid mobilization for lipoprotein assembly by autophagy
Intracellular lipid pools can also be regulated by the macro-
autophagy degradative pathway (here referred as autophagy) [81].
In autophagy, which is induced by stress, nutrient starvation or
infection, a double membrane structure, called a phagophore is
formed from the ER and engulfs a portion of the cytoplasm con-
taining thematerial to be degraded. Once this structure is closed, theautophagosome is mature and it can fuse with lysosomes to pro-
mote degradation of the phagocytosed material [82], with the po-
tential degradation of lipids by lysosomal acid lipases [62]. This
degradative pathway, which is crucial for cellular homeostasis and
which is required during development, has been extensively studied
in human physiopathological contexts including diabetes or obesity
[83,84]. Recently, it has been demonstrated that autophagy partic-
ipates in lipid metabolism in hepatocytes, and a novel concept of
“lipophagy” has been invoked [85]. In that study, the authors
showed that the induction of autophagy can lead to LD breakdown
by direct and speciﬁc interactionwith autophagosomes, and that the
inhibition of autophagy increases the total TG content and LD
number. Together, these data suggest that LDs are bona ﬁde and
speciﬁc targets for autophagy-mediated degradation, and that
autophagy can act as regulators of TG levels in cells that must pro-
cess large amounts of lipids [86,87]. Knowing that apoB also has
been reported to be a putative target for autophagosomal degra-
dation [88], it is tempting to postulate that autophagy participates in
the control of storage and secretion in TRL-secreting cells. This re-
mains to be explored in enterocytes, which process extensive
amounts of dietary lipids coming from the intestinal lumen.
4.2. Lipid droplets as platforms for the metabolism of hydrophobic
molecules
The proteome of LDs is more complex than initially thought and
the nature of the proteins identiﬁed on LDs isolated from enter-
ocytes suggests more extensive functions than simply transient
dietary lipid storage during the process of lipid absorption (Fig. 1).
Some examples are given below.
One of the main functions of LDs is to remove toxic concentra-
tions of free fatty acids in the cytosol. High concentrations of fatty
acids present in the intestinal lumen during the absorptive phase
enter into cells by passive diffusion or speciﬁc transporters [89].
Therefore, it is particularly important for enterocytes to have the
capacity to rapidly synthesize TGs and to produce LDs to detoxify
the fatty acids when the capacity to assemble and secrete chylo-
microns is saturated.
It has been demonstrated recently that retinol dehydrogenase
Rdh10, which is essential for retinoic acid (vitamin A) biosynthesis,
localizes to LDs during acyl ester biosynthesis and that its speciﬁc
activity is strongly increased when targeted to LDs [90]. Rdh10,
which catalyzes the conversion of retinol into retinal, the ﬁrst step of
all-trans-retinoic acid, was identiﬁed in the proteome of LDs isolated
from Caco-2 enterocytes as well as the retinal reductase dhrs3 [4].
Jiang and Napoli [90] suggested that these enzymes are part of a
metabolon that controls retinol homeostasis to/from LDs. Although
this remains to be demonstrated in vivo, the LDs of enterocytes may
as well contribute to retinol homeostasis in the organism.
Short chain dehydrogenase/reductase (SDR) family members
metabolize various compounds including steroids, retinoids, fatty
acid derivatives and xenobiotics [91]. The small intestine is a
xenobiotic-metabolizing organ [92], although this role is usually
devoted to the liver. We have recently shown that 17b-hydroxyste-
roid dehydrogenase 2, which catalyzes the conversion of 17-keto
(e.g. estrone, testosterone) to 17b-hydroxysteroid (e.g. estradiol,
androstenedione) is localized to LDs and interferes with triglyceride
secretion, probably through its capacity to inactivate testosterone
[52]. Indeed, 17b-hydroxysteroid dehydrogenase 2 is also expressed
in the epithelial cells of the small intestine in humans [93].
4.3. Role of lipid droplets in inﬂammation
The gut harbors a microbial ecosystem all along its length,
including in the jejunum [94]. Gram-negative bacteria, present in
S. Demignot et al. / Biochimie 96 (2014) 48e55 53the intestinal microﬂora, release lipopolysaccharide (LPS) upon
lysis, which is a source of circulating LPS. The transfer of LPS into
the circulatory system is favored by dietary lipids [95]. Paracellular
and transcellular routes contribute to LPS movement from intestine
lumen into circulation [96]. Concerning the latter pathway, lipid
micelles formed from the hydrolyzed alimentary lipids and bile
products are important for LPS uptake and enterocytes secrete LPS
on chylomicrons [95,97]. Although of lipophilic nature, it has not
been investigated yet whether LPS can also distribute into cytosolic
LDs. LDs may also play an active role in the production of inﬂam-
matory mediators in response to a variety of inﬂammatory stimuli.
In intestinal epithelial cells such as Caco-2 cells or IEC-6 cells, it has
been shown that cyclooxygenase-2 (Cox-2) localizes to LDs [98,99].
Cox-2 synthesizes prostaglandins from arachidonic acid released
from hydrolysis of phospholipids by cytosolic phospholipase A2.
Interestingly, in microglia, cytosolic phospholipase A2 was shown
to colocalise with LDs induced by LPS but not with LDs induced by
oleic acid treatment [100]. Finally, Cox-2 appears to play an
important role in the repair response upon intestinal injury [101].
Overall, LDs may be sites for prostaglandin production, especially
upon LPS trigger.
4.4. Lipid droplets as platform assemblies for viruses
It is now well documented that members of the Flaviviridae
family, i.e. hepatitis C virus as well as the Dengue virus, use LDs as a
platform for assembly of nascent virions and that this association is
necessary for efﬁcient viral replication [102,103].
Rotaviruses, which belong to the Reoviridae family, infect
epithelial cells of the intestine and are a major cause of acute
gastroenteritis in infants and young children worldwide. Rotavi-
ruses have been shown recently to associate with LDs and the in-
hibition of LD formation negatively affects viral replication [104].
Taken together, manipulating the LDs or the proteins acting in lipid
metabolism might be instrumental for the development of anti-
viral strategies.
5. Conclusion
Research on LDs that forms in the cytosol of enterocytes dur-
ing lipid absorption lagged behind the interest for understanding
the mechanisms of the assembly and the secretion of intestinal
lipoproteins. Because they are usually detected in enterocytes
after a fat load and are very dynamic, LDs are believed to
contribute to the control of the fate of newly synthesized neutral
lipids and thus to control post-prandial hypertriglyceridemia, a
known risk factor for atherosclerosis. The mechanisms that
govern the lipid distribution in the various cellular compartments
of enterocytes are still poorly understood. Indeed, the character-
ization of the proteome of LDs isolated from Caco-2 enterocytes
highlighted candidate proteins that may be involved in lipid
storage, a stock of molecules made available later for the pro-
duction of lipoproteins at periods distant from meals. This re-
mains to be demonstrated. Interestingly, proteins/enzymes
involved in the metabolism of vitamins, steroids and prosta-
glandins were identiﬁed on LDs and this opens new avenues of
research as to the role of LDs as a platform for the metabolism of
hydrophobic molecules and the production of inﬂammatory
mediators in the intestine (Fig. 1).
Obesity and diabetes lead to altered chylomicron secretion, a
process that is linked to cytosolic LD metabolism. It will be of
tremendous interest to determine whether in these pathological
backgrounds the capacity of the enterocytes to regulate LD
composition and function is affected. The recent observation that
the speciﬁc activity of the Rdh10 enzyme is strongly increased aftertranslocation from the ER membrane to the surface of LDs further
highlights the emerging role of LD dynamics in the control of cell
metabolism. We are just beginning to appreciate the full
complexity and importance of the LDs in enterocytes.
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